| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 1,105 | 454 | ||
| Accounts receivable, net | 41 | 87 | ||
| Inventory | 658 | 1,349 | ||
| Short-term investment | 25 | - | ||
| Asset held for sale | 0 | 0 | ||
| Operating lease asset-current | - | 51 | ||
| Deposits and advances | 175 | 212 | ||
| Total current assets | 2,004 | 2,153 | ||
| Intangible assets, net | 4,879 | 1,997 | ||
| Property, plant and equipment, gross | 3,886 | - | ||
| Less accumulated depreciation | 1,711 | - | ||
| Property, plant, and equipment, net | 2,175 | 3,097 | ||
| Claims and advances | 672 | 680 | ||
| Operating lease asset | 13 | 16 | ||
| Total non-current assets | 7,739 | 5,790 | ||
| Total assets | 9,743 | 7,943 | ||
| Accounts payable | 628 | 933 | ||
| Accrued liabilities and others | 886 | 792 | ||
| Total current liabilities | 1,514 | 1,725 | ||
| Long-term loans | 132 | 133 | ||
| Other liabilities | 0 | 0 | ||
| Operating lease liability | 5 | 7 | ||
| Total non-current liabilities | 137 | 140 | ||
| Total liabilities | 1,651 | 1,865 | ||
| Common stock and additional paid-in capital, 0.0001 par value 150,000,000 shares authorized 91,959,112 and 80,878,058 shares issued and outstanding as of september 30, 2025, and march 31, 2025, respectively | 135,774 | 131,920 | ||
| Accumulated other comprehensive loss | -4,854 | -3,499 | ||
| Accumulated deficit | -122,828 | -122,343 | ||
| Total stockholders equity | 8,092 | 6,078 | ||
| Total liabilities and stockholders equity | 9,743 | 7,943 | ||
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)